Validation of a commercially available SARS-CoV-2 serological immunoassay

Meyer, Benjamin; Torriani, Giulia; Yerly Ferrillo, Sabine; Mazza, Léna; Calame, Adrien; Arm-Vernez, Isabelle; Zimmer, Gert; Agoritsas, Thomas; Stirnemann, Jérôme; Spechbach, Hervé; Guessous, Idris; Stringhini, Silvia; Pugin, Jérôme; Roux-Lombard, Pascale; Fontao, Lionel; Siegrist, Claire-Anne; Eckerle, Isabella Anne; Vuilleumier, Nicolas; Kaiser, Laurent; Geneva Center for Emerging Viral Diseases

doi:10.1016/j.cmi.2020.06.024

Scientific article

English

Validation of a commercially available SARS-CoV-2 serological immunoassay

ContributorsMeyer, Benjamin

; Torriani, Giulia; Yerly Ferrillo, Sabine; Mazza, Léna; Calame, Adrien; Arm-Vernez, Isabelle; Zimmer, Gert; Agoritsas, Thomas

; Stirnemann, Jérôme; Spechbach, Hervé; Guessous, Idris; Stringhini, Silvia; Pugin, Jérôme; Roux-Lombard, Pascale; Fontao, Lionel; Siegrist, Claire-Anne; Eckerle, Isabella Anne; Vuilleumier, Nicolas; Kaiser, Laurent; Geneva Center for Emerging Viral Diseases

Published inClinical Microbiology and Infection

Publication date2020

Abstract

Objectives: To validate the diagnostic accuracy of a Euroimmun SARS-CoV-2 IgG and IgA immunoassay for COVID-19. Methods: In this unmatched (1:2) case-control validation study, we used sera of 181 laboratory-confirmed SARS-CoV-2 cases and 326 controls collected before SARS-CoV-2 emergence. Diagnostic accuracy of the immunoassay was assessed against a whole spike protein-based recombinant immunofluorescence assay (rIFA) by receiver operating characteristic (ROC) analyses. Discrepant cases between ELISA and rIFA were further tested by pseudo-neutralization assay.

Keywords

COVID-19
ELISA
Pseudovirus neutralisation assay
Recombinant immunofluorescence assay
SARS-CoV-2
Serological Assays
Serological testing strategy

Affiliation entities

Research groups

Citation (ISO format)

MEYER, Benjamin et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. In: Clinical Microbiology and Infection, 2020. doi: 10.1016/j.cmi.2020.06.024

Article (Accepted version)

Identifiers

PID : unige:138506
DOI : 10.1016/j.cmi.2020.06.024
PMID : 32603801

Commercial URLhttps://www.sciencedirect.com/science/article/pii/S1198743X20303682

Journal ISSN1198-743X

436views

221downloads

Creation07/10/2020 12:34:00 PM

First validation07/10/2020 12:34:00 PM

Update time01/13/2025 4:45:00 PM

Status update01/13/2025 4:45:00 PM

Last indexation01/13/2025 4:45:28 PM

Archive ouverte UNIGE

Validation of a commercially available SARS-CoV-2 serological immunoassay

Technical informations